Moderna (MRNA) Other Non Operating Income (2018 - 2026)

Moderna (MRNA) has 9 years of Other Non Operating Income data on file, last reported at -$18.0 million in Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$18.0 million, down 350.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.0 million (up 69.44% YoY), and the FY2025 annual result was -$8.0 million, up 90.8% from the prior year.
• Other Non Operating Income eased to -$18.0 million in Q1 2026 per MRNA's latest filing, from -$12.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $14.0 million in Q2 2023 and troughed at -$51.0 million in Q3 2023.
• A 5-year average of -$17.6 million and a median of -$13.0 million in 2022 frame the typical range for Other Non Operating Income.
• On a YoY basis, Other Non Operating Income climbed as much as 207.69% in 2023 and fell as far as 628.57% in 2023.
• A 5-year view of Other Non Operating Income shows it stood at -$12.0 million in 2022, then plunged by 225.0% to -$39.0 million in 2023, then grew by 25.64% to -$29.0 million in 2024, then soared by 58.62% to -$12.0 million in 2025, then sank by 50.0% to -$18.0 million in 2026.
• Business Quant data shows MRNA's Other Non Operating Income at -$18.0 million in Q1 2026, -$12.0 million in Q4 2025, and $8.0 million in Q2 2025.